Researchers discovered that pineoblastoma, retinoblastoma and medulloblastoma – severe brain tumours in children that appear to be completely different – actually arise from the same type of cell.
Radiation oncology is a field in remarkable transformation: a deepening global shortage of trained practitioners, persistent inequities in access to treatment – and, on the other side of the ledger, a new generation of technologies, from AI-driven adaptive planning to photon-counting CT, that are expanding what the field can do in ways previously unimaginable. At this year’s World Health Expo…
Functional brain radiosurgery is an application of stereotactic radiosurgery (SRS), representing its newest clinical field. It is a precise, non-invasive medical technique using focused ionising radiation to precisely target specific brain structures to modulate brain function for neurological disorders, psychiatric conditions, or intractable pain. The technology offers “precision without…
Although tumours may at first shrink under therapy, they often regrow or even become resistant. A new study suggests switching to a second treatment while the tumour is still responding to the first.
Radiotherapy is more effective when administered at the right time of day, according to new research. This discovery opens the door to cancer “chronotherapy”, the researchers hope.
Advances in artificial intelligence and multimodal data integration are poised to revolutionise cancer diagnostics – but significant challenges remain before these technologies can be routinely deployed in clinical practice. Professor Manuel Salto-Tellez outlined the steps needed to bridge the gap between complex tumour biology and the relatively simple biomarkers currently available, speaking…
Computational pathology is becoming increasingly important in helping deliver precision medicine to a wider range of patients. Experts at the 37th European Congress of Pathology in Vienna discussed how algorithms can optimise laboratory workflows, generate stronger evidence for molecular tumour boards, and enhance clinical trial design.
Integrating the patient’s voice: A new study shows access to patient-reported outcome (PRO) data improves the consistency of the evaluation of treatment-related side effects in patients with cancer.
A widely used chemotherapy drugs used in cancer treatments can cause heart damage, new research shows. This could be used to adapt treatment regimens - especially in patients with high blood pressure.
A new study shows a significant survival benefit for patients with oropharyngeal cancers treated with proton therapy (IMPT) compared to those treated with traditional radiation therapy (IMRT).
Researchers have discovered that low physical activity is associated with a higher risk of lymphedema. They have also noted that a lymph scanner objectively measures changes in the condition.
Radiotherapy is effective against prostate cancer but can cause side effects. Using AI, scientists found that images originally taken to help position patients could also predict rectal bleeding.
A novel AI-based method can distinguish between progressive brain tumours and radiotherapy-induced necrosis on advanced MRI. This could help clinicians more accurately identify and treat the issues.
After T-cell redirecting therapies, patients are typically hospitalized for several days to watch for side effects. New research shows that these patients can safely be monitored at home.
New immunotherapies are effective against skin cancer, but they can cause serious side effects. New insights suggest that a lower dosage may lead to better outcomes and longer survival.
IDH mutated gliomas are slow-growing brain tumors with a relatively good prognosis. A new study shows that many patients reveal measurable cognitive impairment in the first year after treatment.
Most patients with metastatic colorectal cancer do not respond to immunotherapy—but why? A new study shows how the tumours block the immune system through two complementary mechanisms.
Researchers explore how ultrasound waves can be used to activate chemotherapy drugs only in targeted areas, offering a new path toward safer, more effective cancer treatment.
Hengrui, one of China's leading pharmaceutical companies, is preparing to bring its cancer therapies to international markets. At the ESMO congress in Berlin, Yuting (Shelley) Liu, Head of China Business Development and Strategy of Hengrui Pharma, shared insights into how the company is translating decades of Chinese market experience into a global oncology strategy.
